Limits...
Human umbilical cord mesenchymal stem cells suppress breast cancer tumourigenesis through direct cell-cell contact and internalization.

Chao KC, Yang HT, Chen MW - J. Cell. Mol. Med. (2012)

Bottom Line: Also, treatment with HUMSC injection was efficacious in both in situ and metastatic breast cancers in the animal models.Since HUMSCs were proved to efficaciously suppress breast cancer tumourigenesis both in vitro and in vivo, it is our expectation that treatment with HUMSCs can be a viable therapy for breast cancer in the near future.In addition, we share a new point of view on the role of HUMSCs in foetal development during pregnancy.

View Article: PubMed Central - PubMed

Affiliation: Genomics Research Center, Academia Sinica, Taipei, Taiwan.

Show MeSH

Related in: MedlinePlus

Histopathologic evidence of the suppression of breast cancer tumourigenesis by selected HUMSCs. (A) On haematoxylin and eosin staining, the tumour cells in breast cancer control group (n = 7) were dense and tight, but the tumour cells in HUMSC treatment group (n = 7) were sparse and loose, and condensation of nuclei was observed. On immunohistochemical staining of KI-67, lots of positive cells were noted within the tumour nodule in breast cancer control group (n = 7), but very few positive cells were found in HUMSC treatment group (n = 7). On immunohistochemical staining of cleaved-caspase-3, very few positive cells were found in breast cancer control group (n = 7), but lots of positive cells were noted within the tumour nodule in HUMSC treatment group (n = 7). Scale bars: 20 μm (right) or 100 μm (all others). (B) The KI-67 positive staining rate under high power field of the tumour nodule was 51.21 ± 1.72% in breast cancer control group but was only 10.47 ± 1.61% in HUMSC treatment group. The cleaved-caspase-3 positive staining rate under high power field of the tumour nodule was 0 ± 0% in breast cancer control group but was 75.04 ± 4.65% in HUMSC treatment group.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3822693&req=5

fig05: Histopathologic evidence of the suppression of breast cancer tumourigenesis by selected HUMSCs. (A) On haematoxylin and eosin staining, the tumour cells in breast cancer control group (n = 7) were dense and tight, but the tumour cells in HUMSC treatment group (n = 7) were sparse and loose, and condensation of nuclei was observed. On immunohistochemical staining of KI-67, lots of positive cells were noted within the tumour nodule in breast cancer control group (n = 7), but very few positive cells were found in HUMSC treatment group (n = 7). On immunohistochemical staining of cleaved-caspase-3, very few positive cells were found in breast cancer control group (n = 7), but lots of positive cells were noted within the tumour nodule in HUMSC treatment group (n = 7). Scale bars: 20 μm (right) or 100 μm (all others). (B) The KI-67 positive staining rate under high power field of the tumour nodule was 51.21 ± 1.72% in breast cancer control group but was only 10.47 ± 1.61% in HUMSC treatment group. The cleaved-caspase-3 positive staining rate under high power field of the tumour nodule was 0 ± 0% in breast cancer control group but was 75.04 ± 4.65% in HUMSC treatment group.

Mentions: Compared with breast cancer control group (n = 7), tumour cells in HUMSC treatment group (n = 7) were sparse and loose, with condensation of nuclei noted on haematoxylin and eosin staining. Very few cells with positive KI-67 (a cellular marker for proliferation) staining but lots of cells with positive cleaved-caspase-3 staining were found within the tumour nodule in HUMSC treatment group (Fig. 5A). In breast cancer control group, the KI-67 positive staining rate was 51.21 ± 1.72%, and the cleaved-caspase-3 positive staining rate was 0 ± 0% under high power field of the tumour nodule. However, in HUMSC treatment group, the KI-67 positive staining rate was 10.47 ± 1.61%, while the cleaved-caspase-3 positive staining rate was 75.04 ± 4.65% under high power field of the tumour nodule (Fig. 5B). These findings demonstrate that the tumour cells were no longer largely proliferating and growing, and most of them went into apoptosis following HUMSC treatment.


Human umbilical cord mesenchymal stem cells suppress breast cancer tumourigenesis through direct cell-cell contact and internalization.

Chao KC, Yang HT, Chen MW - J. Cell. Mol. Med. (2012)

Histopathologic evidence of the suppression of breast cancer tumourigenesis by selected HUMSCs. (A) On haematoxylin and eosin staining, the tumour cells in breast cancer control group (n = 7) were dense and tight, but the tumour cells in HUMSC treatment group (n = 7) were sparse and loose, and condensation of nuclei was observed. On immunohistochemical staining of KI-67, lots of positive cells were noted within the tumour nodule in breast cancer control group (n = 7), but very few positive cells were found in HUMSC treatment group (n = 7). On immunohistochemical staining of cleaved-caspase-3, very few positive cells were found in breast cancer control group (n = 7), but lots of positive cells were noted within the tumour nodule in HUMSC treatment group (n = 7). Scale bars: 20 μm (right) or 100 μm (all others). (B) The KI-67 positive staining rate under high power field of the tumour nodule was 51.21 ± 1.72% in breast cancer control group but was only 10.47 ± 1.61% in HUMSC treatment group. The cleaved-caspase-3 positive staining rate under high power field of the tumour nodule was 0 ± 0% in breast cancer control group but was 75.04 ± 4.65% in HUMSC treatment group.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3822693&req=5

fig05: Histopathologic evidence of the suppression of breast cancer tumourigenesis by selected HUMSCs. (A) On haematoxylin and eosin staining, the tumour cells in breast cancer control group (n = 7) were dense and tight, but the tumour cells in HUMSC treatment group (n = 7) were sparse and loose, and condensation of nuclei was observed. On immunohistochemical staining of KI-67, lots of positive cells were noted within the tumour nodule in breast cancer control group (n = 7), but very few positive cells were found in HUMSC treatment group (n = 7). On immunohistochemical staining of cleaved-caspase-3, very few positive cells were found in breast cancer control group (n = 7), but lots of positive cells were noted within the tumour nodule in HUMSC treatment group (n = 7). Scale bars: 20 μm (right) or 100 μm (all others). (B) The KI-67 positive staining rate under high power field of the tumour nodule was 51.21 ± 1.72% in breast cancer control group but was only 10.47 ± 1.61% in HUMSC treatment group. The cleaved-caspase-3 positive staining rate under high power field of the tumour nodule was 0 ± 0% in breast cancer control group but was 75.04 ± 4.65% in HUMSC treatment group.
Mentions: Compared with breast cancer control group (n = 7), tumour cells in HUMSC treatment group (n = 7) were sparse and loose, with condensation of nuclei noted on haematoxylin and eosin staining. Very few cells with positive KI-67 (a cellular marker for proliferation) staining but lots of cells with positive cleaved-caspase-3 staining were found within the tumour nodule in HUMSC treatment group (Fig. 5A). In breast cancer control group, the KI-67 positive staining rate was 51.21 ± 1.72%, and the cleaved-caspase-3 positive staining rate was 0 ± 0% under high power field of the tumour nodule. However, in HUMSC treatment group, the KI-67 positive staining rate was 10.47 ± 1.61%, while the cleaved-caspase-3 positive staining rate was 75.04 ± 4.65% under high power field of the tumour nodule (Fig. 5B). These findings demonstrate that the tumour cells were no longer largely proliferating and growing, and most of them went into apoptosis following HUMSC treatment.

Bottom Line: Also, treatment with HUMSC injection was efficacious in both in situ and metastatic breast cancers in the animal models.Since HUMSCs were proved to efficaciously suppress breast cancer tumourigenesis both in vitro and in vivo, it is our expectation that treatment with HUMSCs can be a viable therapy for breast cancer in the near future.In addition, we share a new point of view on the role of HUMSCs in foetal development during pregnancy.

View Article: PubMed Central - PubMed

Affiliation: Genomics Research Center, Academia Sinica, Taipei, Taiwan.

Show MeSH
Related in: MedlinePlus